| Journal | Addiction (Abingdon, England) |
| Study Type | Clinical Study |
| Population | Human participants |
This item covers developments relevant to cannabis medicine and clinical practice. Clinicians monitoring evidence in this area should review the source material.
The United States Drug Enforcement Administration’s (DEA) proposed rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act marks a significant shift in federal policy. Understanding public sentiment toward this policy is critical for guiding the current cannabis rescheduling effort as well as future reforms. The objective of this study is to characterize public comments submitted to Regulations.gov regarding the DEA’s cannabis rescheduling proposal and identify underlying justifications for support or opposition. A mixed-methods analysis was conducted. Online public comments submitted to Regulations.gov regarding the DEA’s cannabis rescheduling proposal. 42 913 public comments submitted between 21 May and 22 July 2024. Comments were analyzed for sentiment towards the proposed rescheduling (support, oppose or insufficient rescheduling) and thematic justifications using manual and automated natural language processing techniques. A two-stage annotatio
“This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
This study item was assembled from normalized source metadata and pipeline scoring.
